Baylor Scott & White Charles A. Sammons Cancer Center | Strategic Alliance Partners

March 23, 2023

Bradley W. Christensen, MD, discusses findings from the phase 3 VIALE-A trial in patients with acute myeloid leukemia.

January 26, 2023

Joyce O’Shaughnessy, MD, highlights key data from the 2022 San Antonio Breast Cancer Symposium, explains how trastuzumab deruxtecan and CDK4/6 inhibitors are altering the treatment landscape, and discusses novel data on steroid receptor expression in triple-negative breast cancer.

January 20, 2023

Joyce A. O’Shaughnessy, MD, discusses key data from the phase 3 DESTINY-Breast02 and DESTINY-Breast03 trials in metastatic HER2-positive breast cancer.

January 18, 2023

Joyce A. O’Shaughnessy, MD, discusses key results from the phase 3 EMERALD trial of elacestrant, and the potential effects of the agent’s approval on the use of oral selective estrogen receptor degraders for hormone receptor–positive, HER2-negative breast cancer.

December 22, 2022

Edward J. Pearson, MD, and colleagues, discuss the expanded role of targeted therapies in the treatment of patients with hematologic malignancies.

September 12, 2022

OncLive® will be LIVE with OncLive® News Network: On Location at the 2022 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.

June 25, 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab for the adjuvant treatment of adult patients with esophageal or gastroesophageal junction cancer who have residual pathologic disease after previous neoadjuvant chemoradiotherapy.

June 05, 2021

Selumetinib did not elicit clinical activity in pediatric and young adult patients with refractory cancers who had actionable mutations in the RAS/RAF/MAPK1/2-ERK pathway.

May 24, 2021

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

May 22, 2021

YoungNa Lee-Kim, MD, shares advice on how to advance as an oncology fellow.

May 15, 2021

Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

November 11, 2020

Seth P. Lerner, MD, FACS, discusses the complexities of treating LG-UTUC and how mitomycin gel for instillation addresses an unmet need in this space.

October 07, 2020

Ronan J. Kelly, MD, MBA, explains how the results of the KEYNOTE-407 trial have positioned pembrolizumab plus chemotherapy as the frontline standard of care in this setting.

August 18, 2020

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

April 15, 2020

Joyce A. O'Shaughnessy, MD, discusses the design and findings of the plasmaMATCH trial and ongoing research with targeted therapy in breast cancer.

May 20, 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the impact of immunotherapy in squamous non–small cell lung cancer.

May 14, 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the 10 Baylor Scott & White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the outlook of patients with ALK-positive non–small cell lung cancer (NSCLC).

May 07, 2019

Ronan J. Kelly, MD, MBA, chief of oncology for the ten Baylor Scott and White Health's North Texas Cancer Centers and director of oncology on the campus of Baylor Charles A. Sammons Cancer Center at Baylor University Medical Center, discusses the treatment of patients with ALK-positive non–small cell lung cancer.

May 03, 2019

The rationale for frontline chemoimmunotherapy in stage IV nonsquamous non–small cell lung cancer, now made evident by several phase III trials, stems from its synergistic activity, stimulatory effects on neoantigens, and tolerable safety profile.

May 02, 2019

Eric S. Nadler, MD, medical oncologist, Baylor University Medical Center, medical director, US Oncology Health Informatics and Internet Technology, discusses the IMpower131 study in squamous metastatic non–small cell lung cancer.